A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)
Status:
Completed
Trial end date:
2012-01-09
Target enrollment:
Participant gender:
Summary
This was a 2-part study in participants with allergen-induced asthma. It included a
procedural pilot component (Part 1). Part 1 tested the key procedures and timing of Part 2;
no study drug was administered during Part 1. Part 2 included a pre-randomization placebo
run-in (Period 1) and 3 treatment periods (Periods 2, 3, and 4) during which participants
were randomized to receive double-blind placebo, MK-1029 60 mg or MK-1029 500 mg in a
crossover design. The treatment periods were followed by a minimum 21-day washout. Part 2
assessed allergen-induced sputum eosinophils and allergen-induced late asthmatic response
(LAR) compared to placebo.